基于PCSK9调控CD36、介导RCT探讨补肾中药复方防治动脉粥样硬化的研究策略  

Study on prevention and treatment of atherosclerosis by compound Chinese medicine for reinforcing kidney based on PCSK9 targeting CD36,mediating RCT

作　　者：贾庆玲 申定珠[1] JIA Qingling;SHEN Dingzhu(Shanghai Geriatrics Institute of Chinese Medicine / Shanghai University of Traditional Chinese Medicine, Shanghai 200031, China)

机构地区：[1]上海中医药大学/上海市中医老年医学研究所,上海200031

出　　处：《中国医药导报》2019年第7期116-119,共4页China Medical Herald

基　　金：国家自然科学基金面上项目(81873348);上海市自然科学基金项目(16ZR1433900);上海市卫计委科研项目(201640217);上海中医药大学"研究生创新培养项目"专项研究(Y201858)

摘　　要：动脉粥样硬化(AS)是心脑血管事件的共同病理基础。胆固醇逆向转运(RCT)在AS进程中发挥关键作用。前蛋白转化酶枯草溶菌素9(PCSK9)、分化抗原36(CD36)与RCT密切相关。结合补肾中药复方干预治疗AS的前期研究,本文拟从PCSK9调控CD36、介导RCT角度探讨补肾中药复方防治AS的研究策略。Atherosclerosis(AS) is the common pathological basis of cardiovascular and cerebrovascular events. Reverse cholesterol transport(RCT) plays an important role in the progress of AS. Proprotein convertase subtilisin/kexin type 9(PCSK9) and cluster of differentiation 36(CD36) are closely related to RCT. Combined with the preliminary research that compound Chinese medicine for reinforcing kidney can intervene AS, this paper intends to explore the research strategy that compound Chinese medicine for reinforcing kidney can prevent and cure AS by PCSK9 targeting CD36 and mediating RCT.

关 键 词：动脉粥样硬化 胆固醇逆向转运 前蛋白转化酶枯草溶菌素9 分化抗原36 补肾中药复方 

分 类 号：R543[医药卫生—心血管疾病]